Method of treating men with testosterone supplement and 5alpha-reductase inhibitor

Details for Australian Patent Application No. 2006229840 (hide)

Owner Merck Sharp & Dohme Corp.

Inventors Meehan, Alan

Agent Spruson & Ferguson

Pub. Number AU-B-2006229840

PCT Pub. Number WO2006/104762

Priority 60/665,174 25.03.05 US

Filing date 21 March 2006

Wipo publication date 5 October 2006

Acceptance publication date 23 December 2010

International Classifications

A61K 31/435 (2006.01) - having six-membered rings with one nitrogen as the only ring hetero atom

A61K 31/473 (2006.01) - ortho- or peri-condensed with carbocyclic ring systems, e.g. acridines, phenanthridines

A61K 31/568 (2006.01) - substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstane, testosterone

Event Publications

20 September 2007 PCT application entered the National Phase

  PCT publication WO2006/104762 Priority application(s): WO2006/104762

28 January 2010 Alteration of Name

  The name of the applicant has been altered to Merck Sharp & Dohme Corp.

23 December 2010 Application Accepted

  Published as AU-B-2006229840

21 April 2011 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006229865-Process and apparatus for thermally integrated hydrogen generation system

2006229809-Wagering games with unlockable bonus rounds